Stock in Focus: Regeneron Pharmaceuticals (REGN)

Company Profile:

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Recent News:

Citi analyst Mohit Bansal upgraded the biotechnology company to buy from neutral on optimism about its eczema drug, Dupixent. Dupixent has plenty of potential for growth beyond its current label, Bansal said, according to Dow Jones.

On Dec. 29, 2020, the company announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19.

 

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

REGN’s strengths can be seen in its better growth and strong profitability compared with its peers. Its revenue has increased over recent years. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator, the RSI stands at 51.91 with positive bias. We rate Regeneron Pharmaceuticals (REGN) a STRONG BUY.

About the Author

has written 13382 stories on this site.

Copyright © 2012 Nine Stocks